Development of potent monoclonal antibody auristatin conjugates for cancer therapy

Nature Biotechnology
Svetlana O DoroninaPeter D Senter

Abstract

We describe the in vitro and in vivo properties of monoclonal antibody (mAb)-drug conjugates consisting of the potent synthetic dolastatin 10 analogs auristatin E (AE) and monomethylauristatin E (MMAE), linked to the chimeric mAbs cBR96 (specific to Lewis Y on carcinomas) and cAC10 (specific to CD30 on hematological malignancies). The linkers used for conjugate formation included an acid-labile hydrazone and protease-sensitive dipeptides, leading to uniformly substituted conjugates that efficiently released active drug in the lysosomes of antigen-positive (Ag+) tumor cells. The peptide-linked mAb-valine-citrulline-MMAE and mAb-phenylalanine-lysine-MMAE conjugates were much more stable in buffers and plasma than the conjugates of mAb and the hydrazone of 5-benzoylvaleric acid-AE ester (AEVB). As a result, the mAb-Val-Cit-MMAE conjugates exhibited greater in vitro specificity and lower in vivo toxicity than corresponding hydrazone conjugates. In vivo studies demonstrated that the peptide-linked conjugates induced regressions and cures of established tumor xenografts with therapeutic indices as high as 60-fold. These conjugates illustrate the importance of linker technology, drug potency and conjugation methodology in developing s...Continue Reading

References

May 1, 1981·Journal of Medicinal Chemistry·P L CarlJ A Katzenellenbogen
Aug 6, 1996·Proceedings of the National Academy of Sciences of the United States of America·C LiuR V Chari
Jan 1, 1997·Fortschritte der Chemie organischer Naturstoffe = Progress in the chemistry of organic natural products. Progrès dans la chimie des substances organiques naturelles·G R Pettit
May 23, 1998·Annual Review of Pharmacology and Toxicology·T Satoh, M Hosokawa
Oct 8, 1999·Pharmacology & Therapeutics·G M Dubowchik, M A Walker
Feb 17, 2000·Clinica Chimica Acta; International Journal of Clinical Chemistry·J E KoblinskiB F Sloane
Jun 1, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M N SalehA F LoBuglio
Aug 31, 2000·Japanese Journal of Cancer Research : Gann·M OtaniT Nakayama
Mar 17, 2001·Nature Reviews. Molecular Cell Biology·Y Yarden, M X Sliwkowski
Oct 2, 2001·Critical Reviews in Oncology/hematology·L S Schwartzberg
Mar 22, 2002·Nature Reviews. Cancer·P Carter
Jul 13, 2002·Expert Review of Anticancer Therapy·K M King, A Younes
Dec 13, 2002·Journal of Medicinal Chemistry·Iwao OjimaRavi V J Chari

❮ Previous
Next ❯

Citations

Jun 2, 2007·Cancer Chemotherapy and Pharmacology·Vincent A PollackWilliam J LaRochelle
Jul 24, 2012·Cancer Chemotherapy and Pharmacology·Diego A GianolioBeverly A Teicher
Jul 11, 2012·Pharmaceutical Research·Gary D Stack, John J Walsh
May 7, 2010·Current Hematologic Malignancy Reports·Kelley V Foyil, Nancy L Bartlett
Oct 16, 2012·Current Hematologic Malignancy Reports·Joseph Vadakara, Barbara Pro
Jun 16, 2005·Bioorganic & Medicinal Chemistry·Stanislav JaraczIwao Ojima
Apr 30, 2013·Bioorganic & Medicinal Chemistry·Hong X DingChristopher J O'Donnell
Jul 13, 2013·European Journal of Medicinal Chemistry·Thibaut LegiganSébastien Papot
Aug 21, 2007·Accounts of Chemical Research·Ravi V J Chari
Sep 22, 2005·Bioconjugate Chemistry·Michael M C SunStephen C Alley
Oct 23, 2008·Journal of Medicinal Chemistry·Sung-Ju MoonDavid M Goldenberg
Sep 10, 2005·Nature Biotechnology·Anna M Wu, Peter D Senter
Jan 31, 2006·Nature Biotechnology·Bonnee RubinfeldPaul Polakis
Feb 28, 2006·Nature Biotechnology·Daniella HerszfeldMartin F Pera
Mar 30, 2007·Nature Clinical Practice. Oncology·Alejandro D Ricart, Anthony W Tolcher
Jan 21, 2006·Nature Reviews. Drug Discovery·David SchramaJürgen C Becker
Jan 4, 2012·Nature Reviews. Drug Discovery·Anas YounesPeter Kirkpatrick
Nov 5, 2010·The New England Journal of Medicine·Anas YounesAndres Forero-Torres
May 23, 2012·The Journal of Biological Chemistry·Youjun ChenPaul Polakis
Dec 19, 2012·Hybridoma·Mehdi EvazalipourKobra Omidfar
Jul 31, 2009·Journal of the National Cancer Institute·Jeong-Won LeeAnil K Sood
Oct 12, 2011·Current Opinion in Oncology·Anas Younes
Jun 10, 2008·The Cancer Journal·Paul J Carter, Peter D Senter
Feb 16, 2006·Journal of Nanobiotechnology·Pratik SinghMarianne Manchester
Oct 10, 2006·The AAPS Journal·Yingjuan LuEmanuela Sega
Sep 9, 2005·International Journal of Hematology·Yiwen Li, Zhenping Zhu
Apr 6, 2011·Immunotherapy·Kelley V Foyil, Nancy L Bartlett
Jan 22, 2013·Bioanalysis·Surinder KaurMontserrat Carrasco-Triguero
Mar 1, 2011·Therapeutic Delivery·Victor S Goldmacher, Yelena V Kovtun
Jul 24, 2012·Therapeutic Delivery·Saileta PrabhuBert L Lum
Aug 25, 2012·Future Medicinal Chemistry·Verena M AhrensAnnette G Beck-Sickinger
Feb 8, 2014·Journal of Pharmaceutical and Biomedical Analysis·Yi LiNik Chetwyn
Mar 9, 2013·Biochimica Et Biophysica Acta·Lanhong ZhengMi Sun
Feb 6, 2014·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Christos Vaklavas, Andres Forero
Dec 3, 2005·Proceedings of the National Academy of Sciences of the United States of America·Cary D AustinSuzie J Scales
Nov 14, 2013·Targeted Oncology·François-Clément Bidard, Olivier Trédan
Nov 22, 2013·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Matthew MeiRobert Chen

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.